ArticleIndian journal of clinical biochemistry : IJCB2025
Utility of Urinary Biomarkers for Diagnosis of Acute Kidney Injury (AKI) in COVID-19.
Article in Indian journal of clinical biochemistry : IJCB, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exploring Kidney Injury Molecule-1 and HAVCR1 Polymorphisms as Predictive Biomarkers in Chronic Kidney Disease.Kidney diseases (Basel, Switzerland)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute kidney injury (AKI) is a complication of COVID-19 and urinary biomarkers of renal "stress" and "injury" can be utilised for an early diagnosis. In this prospective observational study, critically-ill adult patients with COVID-19 disease from November 2020 to May 2021 were recruited and urine samples collected at the time of admission to ICU, and subsequently at 12, 24 and 48 h and analysed for biomarkers of "renal injury" namely KIM-1, NGAL, IL-18, and cell cycle arrest biomarker IGFBP-7 and TIMP-2 which have been reported to increase following renal stress. Spot urine samples were collected and to adjust for dilution, sample volume and rate of urine production, assays of the biomarkers were normalised by dividing the values with urinary creatinine concentration. The incidence of AKI in our study was 22.64% (24/106). Patients in the AKI group were older with significantly higher requirements for invasive mechanical ventilation, inotropic support, longer hospital stay, and higher mortality. Diagnostic performance of various biomarkers to predict AKI was compared with receiver operator characteristics curve analysis. TIMP-2 × IGFBP7 > 0.301 (ng/ml)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.